Michael Ackermann is the CEO of Tarsus Pharmaceuticals, a company focused on developing new treatments in the eye care sector. With a Ph.D. in Biomedical Sciences, he has a solid background in pharmaceuticals. His expertise stems from years of leadership...

Michael Ackermann is the CEO of Tarsus Pharmaceuticals, a company focused on developing new treatments in the eye care sector. With a Ph.D. in Biomedical Sciences, he has a solid background in pharmaceuticals. His expertise stems from years of leadership in the industry, including roles at Allergan and as the CEO of Oculeve, which was acquired by Allergan. His strategic insights led to Tarsus's growth and innovation in creating therapies for eye conditions. In late 2022, he transitioned from being the Chairperson of the Board to a consultant role. Akermann's insider trading activity shows he has had significant holdings, peaking at around $51.62 million before experiencing some fluctuations, which indicates he is well-invested in his company's success. In 2020, his total compensation included a base salary of $532,000 and a bonus, reflecting the company's performance and his contributions. His journey through various leadership positions has made him a key player in shaping Tarsus Pharmaceuticals' direction in the competitive landscape of eye care.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Tarsus Pharmaceuticals, Inc. CEOs

T

Michael Ackermann

Ex-CEO of Tarsus Pharmaceuticals, Inc.

Education

Ph.D. in Biomedical Sciences

Field of Expertise

Healthcare & Life Sciences - Pharmaceuticals

Sector of Economy

Healthcare

Born

January 1, 1969 - 56 years ago

CEO of Tarsus Pharmaceuticals, Inc. for

1 year 2 months (Sep 2019 - Nov 2020)

Previous Experience

Chief Executive Officer of Tarsus Pharmaceuticals, Inc.

Rivals

Competitors/colleagues of Michael Ackermann

Holdings

See how much did Michael Ackermann make over time.

Michael Ackermann has shown a strong commitment to Tarsus Pharmaceuticals with notable insider trading activities. His holdings peaked at around $51.62 million in January 2021, showcasing his significant investment in the company. Over the months, these holdings varied quite a...

Michael Ackermann has shown a strong commitment to Tarsus Pharmaceuticals with notable insider trading activities. His holdings peaked at around $51.62 million in January 2021, showcasing his significant investment in the company. Over the months, these holdings varied quite a bit, indicating fluctuations based on the company's stock performance. For instance, in November 2020, his holdings were valued at $28.36 million, which climbed to $45.33 million by December of the same year. This fluctuation shows Ackermann's belief in Tarsus and its potential for growth. As of now, his holdings reflect continued involvement and confidence in the company's future trajectory.

No data yet.

Total Stock Sold

$756.61K

TARS

$756.61K

29,165 TARS shares

What if they kept their stock?

If Michael Ackermann didn't sell their stock, today they would have:
Extra TARS29,165 shares worth $600.22K.
This is -20.67% and $156.40K less than what they got when they sold the stock.

Insider Trading

See recent insider trades of Michael Ackermann.

TARS

$1.35M

TARS at $13.50/share

May 5, 2022

Purchase

TARS

$147.36K

TARS at $25.26/share

Dec 1, 2021

Sale

TARS

$163.15K

TARS at $27.97/share

Nov 1, 2021

Sale

TARS

$146.49K

TARS at $26.01/share

Oct 12, 2021

Sale

TARS

$5.01K

TARS at $25.03/share

Oct 8, 2021

Sale

TARS

$147.24K

TARS at $25.24/share

Sep 1, 2021

Sale

TARS

$15.62K

TARS at $25.15/share

Aug 11, 2021

Sale

TARS

$95.73K

TARS at $25.00/share

Aug 6, 2021

Sale

TARS

$34.58K

TARS at $25.01/share

Aug 5, 2021

Sale

TARS

4,257 shares

TARS

Jun 15, 2021

Received

Compensation History

See how much did Michael Ackermann make over time.

In 2020, Michael Ackermann's total compensation reflected his commitment and performance as CEO of Tarsus Pharmaceuticals. He earned a base salary of $532,000, coupled with a bonus amounting to approximately $211,484, which tied closely to the company's success that year. Overall, his total compensation reached around $765,304, excluding stock awards. This structure highlights how his remuneration is linked to the company's performance and his ability to steer it successfully in the pharmaceutical landscape. Notably, while he didn't have reported stock vesting in that year, the substantial stock options granted suggest a long-term focus on aligning his interests with those of shareholders. His approach to compensation illustrates the balance between immediate rewards and future growth potential for the company.

Year

2020

Total Compensation

$758.30K

Salary

$532.00K

Board Justification

The compensation committee seeks to support the Company’s overall business strategy and objectives, attract and retain key executives, link compensation with business objectives and organizational performance, and provide competitive compensation opportunities.

Bonus

$211.48K

Board Justification

The amounts in this column reflect annual cash bonuses paid with respect to the applicable fiscal year and, in the case of Mr. Greenstein, a $40,000 sign on bonus he was paid in fiscal 2020.

Other

$14.82K

Board Justification

The amounts in this column reflect premiums for medical benefits, or waiver allowances if benefits were not elected, paid to each of our named executive officers.

Restricted Stock

$0.00(0 common stock)

Board Justification

No stock was reported as vested for the CEO in 2020.

Performance Metrics

The target bonus rate (as a percentage of base salary) was 50% for Dr. Azamian.

Other Tarsus Pharmaceuticals, Inc. CEOs

Here are other CEOs of Tarsus Pharmaceuticals, Inc.

Bobak Azamian

CEO of Tarsus Pharmaceuticals, Inc.

November 2020 - Present